Wild-type p53 has a major role in the response and execution of apoptosis after chemotherapy in many cancers. Although high levels of wild-type p53 and hardly any TP53 mutations are found in testicular cancer (TC), chemotherapy resistance is still observed in a significant subgroup of TC patients. In the present study, we demonstrate that p53 resides in a complex with MDM2 at higher cisplatin concentrations in cisplatin-resistant human TC cells compared with cisplatin-sensitive TC cells. Inhibition of the MDM2-p53 interaction using either Nutlin-3 or MDM2 RNA interference resulted in hyperactivation of the p53 pathway and a strong induction of apoptosis in cisplatin-sensitive and -resistant TC cells. Suppression of wild-type p53 induced resistance to Nutlin-3 in TC cells, demonstrating the key role of p53 for Nutlin-3 sensitivity. More specifically, our results indicate that p53-dependent induction of Fas membrane expression (Bthreefold) and enhanced Fas/FasL interactions at the cell surface are important mechanisms of Nutlin-3-induced apoptosis in TC cells. Importantly, an analogous Fas-dependent mechanism of apoptosis upon Nutlin-3 treatment is executed in wild-type p53 expressing Hodgkin lymphoma and acute myeloid leukaemia cell lines. Finally, we demonstrate that Nutlin-3 strongly augmented cisplatin-induced apoptosis and cell kill via the Fas death receptor pathway. This effect is most pronounced in cisplatin-resistant TC cells. Most testicular cancer (TC) patients respond well to cisplatinbased chemotherapy; however, there is still a subset of these young patients that will die because of chemo-resistant or chemo-refractory disease.
Tumour protein p53 (TP53) is the most frequently mutated gene in human cancers. 7, 8 Surprisingly, in human TCs almost no TP53 mutations are found and wild-type p53 is expressed at high levels in the majority of TCs. 9 Despite the increasing knowledge about p53 as a transactivator and cellular gatekeeper for cell growth and division, the effects of wild-type p53 (and mutated p53) on drug sensitivity of human tumours including TC are still not clear. We have previously shown that the response to cisplatin-induced DNA damage in TC cell lines is related to an induction of p53 expression and activation of the Fas death receptor pathway. 2, 9 Several other studies have reported the effect of wild-type p53 expression on chemo-sensitivity of human TC cell lines with contrasting and sometimes conflicting results. 3, [10] [11] [12] [13] [14] [15] Tumours that retain wild-type p53 are supposed to have other defects in the p53 pathway, such as the presence of microRNA (miR)-371-373, miR-106b-seed-family members or cytoplasmic p21, the lack of phosphatase and tensin homologue (PTEN) expression or the increased mouse double minute 2 (MDM2) expression. [16] [17] [18] [19] MDM2, as transcriptional target of p53, is the main negative feedback regulator of p53. By binding to the transactivation domain of p53, MDM2 is able to regulate p53 activity and stability via several mechanisms such as promoting p53 degradation through ubiquitination, stimulating p53 nuclear export, and inhibiting acetylation of p53. 7 Interfering in the MDM2-p53 interaction, with small molecules like RITA and Nutlin-3, provides an attractive strategy for (re)activating wild-type p53 in a non-genotoxic way. This (re)activation leads to cell-cycle arrest and or apoptosis in tumour cells with wild-type p53. [20] [21] [22] [23] Restoration of p53 function by Nutlin-3 may thus have profound therapeutic effect on tumours that have retained wild-type p53, particularly if MDM2 activity is disproportionally increased. 23 Recently, Nutlin-3-induced apoptosis was investigated in a small panel of TC cell lines, and only additive effects were seen in combination with cisplatin. However, no mechanistic insights in Nutlin-3-induced apoptosis were offered. 24, 25 In this study, we explore the potential of disrupting the MDM2-p53 interaction as a mean to activate p53 in TC. The role of p53 and MDM2 in cisplatin-induced apoptosis has been investigated using cisplatin-sensitive and -resistant human TC models. Finally, the importance of the Fas death receptor pathway in Nutlin-3 induced apoptosis has been studied.
Results
P53 and MDM2 cellular localisation and cisplatin response in TC Cells. In the present study, we have used a panel of cisplatin-sensitive and -resistant wild-type p53 expressing TC cell lines to compare cisplatin responses (Table 1) with the cellular localisation of p53 and MDM2, and MDM2-p53 complex formation (Figures 1a-c, Supplementary Figure 1 ). With immunofluorescence, we found that p53 is predominantly localised to the cytoplasm, while MDM2 was mainly present in the nucleus in all four cell lines ( Figure 1a and Supplementary Figure 1 ). After exposure of cells to 8 mM cisplatin, p53 became more nuclear localised, while MDM2 was observed in both the nucleus and cytoplasm of cisplatinsensitive Tera ( Figure 1a ) and 833KE (data not shown) cells. In contrast, in the intrinsically cisplatin-resistant TC cell lines, Scha, and 2102EP, and in Tera-CP, an acquired cisplatinresistant subline of Tera, p53 maintained localised in the cytoplasm, while MDM2 retained its nuclear localisation upon treatment with 8 mM cisplatin (Supplementary Figure 1) . Only at higher cisplatin concentrations, p53 became more nuclear localised, while MDM2 expression was then observed in both the nucleus and the cytoplasm (results not shown). Immunoprecipitation (IP) has been used to determine whether the observed shift in cellular localisation of p53 and MDM2 after cisplatin treatment affects MDM2-p53 complex formation (Figures 1b and c) . Note that we have used lower cisplatin concentrations for the cisplatin-sensitive Tera cell line compared with the cisplatin-resistant cell lines. Despite the strong induction of both p53 and MDM2 with increasing concentrations of cisplatin in Tera cells (lysates Figure 1b) , IP experiments indicated a relative decrease in p53 being in complex with MDM2 in favour of unbound p53 upon increasing cisplatin concentrations (Figures 1b and c) . In contrast, sustained MDM2-p53 complex formation was still detected in cisplatin-resistant TC cells at relatively high cisplatin concentrations (up to 8 mM). Eventually, MDM2-p53 complexes in these cells were (partially) lost at cisplatin concentrations above 16 mM (Figures 1b and c) . Taken together, our results suggest that high sensitivity for cisplatin cytotoxicity and cisplatin-induced apoptosis is related to a reduction in MDM2-p53 complex formation and a change in p53 cellular localisation.
Apoptosis induction after disruption of the MDM2-p53 interaction depends on wild-type p53. To investigate the importance of the MDM2-p53 complex formation in preventing apoptosis in TC, we have used the small molecule inhibitors 'reactivation of p53 and induction of tumours cell apoptosis' (RITA) and Nutlin-3 that are supposed to disrupt the MDM2-p53 interaction. RITA induced massive apoptosis at nanomolar concentrations in the absence of transcriptional activation of any of the p53 targets tested (p53, MDM2, p21, and Fas). Furthermore, downregulation of p53 with small-interfering RNA (siRNA) did not interfere with the apoptosis induction by RITA (Supplementary Figure 2a) . Moreover, treatment with RITA induced caspase-dependent apoptosis in NCCIT, the TC cell line expressing mutant p53 (Supplementary Figure 2a) , indicating that at least in TC cells RITA induces apoptosis independent of wild-type p53.
Therefore, further research was focused on the effects of the small molecule inhibitor Nutlin-3 in wild-type p53-expressing TC cells. Treatment of cisplatin-sensitive Tera and 833KE cells and cisplatin-resistant Tera-CP, Scha, and Nutlin-3 enhancement ratios were calculated by dividing the IC 50 for cisplatin alone by the IC 50 for the combination with cisplatin and 1 mM Nutlin-3.
d The p53 status of the cells was previously described 3, 30 Targeting MDM2/p53 overcomes cisplatin resistance Next, we proved that the observed transcriptional activity and apoptosis induction after Nutlin-3 treatment are p53-dependent effects, because suppression of p53 with p53 siRNA was accompanied by a reduced apoptotic response to Nutlin-3 treatment in all wild-type p53-expressing cells (Figures 3a-c and Supplementary Figure 3a) . In addition, p53 suppression prevented the upregulation of MDM2 and p21 levels after Nutlin-3 treatment (Figure 3d ). Transfection with the scrambled siRNA had no effect on p53 levels or Nutlin-3-induced apoptosis, further demonstrating the wild-type p53-dependent effect of Nutlin-3 in TC cells.
Increased Fas death receptor expression in TC cells after Nutlin-3 treatment. Induction of the Fas death receptor membrane expression after drug treatment has been observed in several cell lines, which can occur in a p53-dependent manner. 2, 5, [26] [27] [28] [29] [30] In line with our previous results, Fas-dependent apoptosis after Nutlin-3 treatment. We previously reported that cisplatin-induced apoptosis is depending on activation of the Fas/ Fas Ligand (FasL) system in cisplatin-sensitive TC cells. 2 Activation of the Fas/ FasL system was largely impaired in the cisplatin-resistant Tera-CP and Scha cells. 2 To further investigate the importance of Fas upregulation for Nutlin-3-induced apoptosis, we inhibited the Figure 3c) . Interfering in the Fas/FasL system, however, had no effect on the induction of p53 by Nutlin-3 ( Figure 4d and Supplementary Figure 3c ). Our results demonstrate that the massive apoptosis induction in TC cells after Nutlin-3 treatment is to a large extent dependent on the activation of the Fas death receptor pathway.
We have demonstrated that high levels of cytoplasmic localised p21 protected Scha and 2102EP cells against cisplatin-induced apoptosis, probably by interfering with Fas-death receptor signalling. 19, 30 In this study, we show that treatment with a relatively low dose of Nutlin-3 (4 mM) led to higher levels of cytoplasmic localised p21 that was most pronounced in 2102EP and Scha cells (Figure 2c Treatment with high-dose Nutlin-3 further increased the fold of induction of p21 in the wild-type p53-expressing TC cells, but p21 seems to no longer be able to inhibit apoptosis induction. Therefore, the importance of cytoplasmic p21 in inhibiting Nutlin-3-induced apoptosis has been further defined using an siRNA approach. Downregulation of p21 (Supplementary Figure 3e) led to an increase in Nutlin-3-induced apoptosis (at 4 mM) in Scha and 2102EP cells, as demonstrated by an increase in PARP cleavage (Supplementary Figure  3e) . Thus, p21 can have a role in inhibiting Nutlin-3-induced apoptosis. Next, we addressed the question, if the Fas death receptor pathway also has an important role in Nutlin-3-induced apoptosis in other non-testicular tumour cell types. To this end, we analysed Hodgkin lymphoma and acute myeloid leukaemia (AML) cell lines, which are also known to be sensitive to Nutlin-3. 21, 22 Blocking of FasL with NOK-1 considerably reduces the apoptotic response and PARP cleavage after Nutlin-3 treatment in the wild-type p53-expressing Hodgkin lymphoma cell lines KM-H2 and L540 (Figure 5a ), as well as in the wild-type p53-expressing MOLM-13 AML cells (Figure 5b ). In addition, no effect of either Nutlin-3 treatment or blocking of the Fas/FasL interaction was observed in OCI-AML3 or the mutant p53 expressing Hodgkin lymphoma and AML cell lines, L428 (Figure 5a ) and HL-60 (Figure 5b ), respectively. This shows that the Fas death receptor pathway also has an important role in Nutlin-3-induced apoptosis in wild-type p53 expressing cell lines derived from other tumour types. Table 1 ). As expected, the combination with Nutlin-3 has no potentiating effect on cisplatin-induced cytotoxicity in the mutant p53 cell line NCCIT (Supplementary Figure 4b) . The mechanism of sensitisation has been further investigated in the acquired cisplatin-resistant cell model (Figures 6b and e) and intrinsic cisplatin-resistant cell lines (Supplementary Figure 5 ). Combined treatment with Nutlin-3 and cisplatin strongly enhanced p53 upregulation compared with the effect of either cisplatin or Nutlin-3 treatment alone on p53 levels. This was accompanied by a large induction of apoptosis as reflected in almost complete PARP cleavage with the combination and minimal PARP cleavage with either drug alone, which was most contrasting for Tera-CP (Figures 6b and  c) and Scha and 2102EP (Supplementary Figures 5a and b) .
To investigate if the Fas death receptor pathway also has an important role in apoptosis-induction after combination treatment, Fas membrane expression levels were determined. Nutlin-3 in combination with cisplatin resulted in much higher Fas membrane expression levels compared with the levels found after treatment with Nutlin-3 or cisplatin alone in wildtype p53-expressing TC cell lines (Figure 6d and Supplementary Figure 5c ). No induction of Fas membrane expression was observed in the mutant p53-expressing NCCIT after the various treatments (Supplementary Figure 3b) . Additionally, blocking of FasL with NOK-1 reduced the apoptotic response of wild-type p53-expressing TC cells to the combined treatment of Nutlin-3 and cisplatin (Figure 6e and Supplementary Figure 5d) . Suppression of MDM2 with siRNA extremely sensitised TC cells to cisplatin-induced apoptosis, almost similar to our observations with Nutlin-3. Moreover, p53 expression and Fas membrane expression were strongly upregulated after treatment with MDM2 siRNA in combination with cisplatin, especially in the cisplatin-resistant TC cells. This demonstrates that the release of the negative feedback on p53 by MDM2 is the important event for enhancing cisplatin-induced apoptosis in TC cells (Figures 6b-d and Supplementary Figures 5a-c) .
Taken together, these results indicate that targeting MDM2 in combination with cisplatin treatment overcomes both Targeting MDM2/p53 overcomes cisplatin resistance R Koster et al intrinsic as well as acquired-resistance to cisplatin in wild-type p53-expressing TC cells, and is largely dependent on activation of the Fas death receptor pathway.
Discussion
In the present study, we demonstrate that wild-type p53 is sustained in complex with MDM2 in cisplatin-resistant TC cell lines following treatment with therapeutically relevant cisplatin concentrations. Our results indicate that interfering in the MDM2-p53 interaction through the small molecule compound Nutlin-3, sensitises wild-type p53-expressing TC cells for apoptosis. Combining Nutlin-3 with cisplatin, the most important therapeutic drug in the treatment of TC patients, results in hyper-activation of the p53 pathway, largely sensitises both intrinsic as well as acquired cisplatin-resistant TC cells to apoptosis via the Fas/FasL death receptor pathway, and strongly reduces cell survival. These results indicate that targeting the MDM2/p53 axis, in combination with standard cisplatin-based chemotherapeutic treatment, is an attractive therapeutic strategy to pursue for cisplatin-resistant/ refractory TC ( Figure 7 ). P53-interacting proteins, such as MDM2, are important regulators of wild-type p53 functionality. 7, 20 The lack of TP53 mutations in TC has led to the hypothesis that constitutively expressed p53 is functionally inactive. 31 Surprisingly high levels of wild-type p53 have been frequently observed in TC. These levels correlate with expression levels of the p53 transcriptional target MDM2, suggesting that p53 is functional in TC. 11, 13, 17 In this study, we show that treatment with the selective MDM2 antagonist Nutlin-3 causes a high induction of both p53 and MDM2, a massive induction of apoptosis, and a strong reduction in cell survival in cisplatin-sensitive as well as cisplatin-resistant TC cell lines. In addition, siRNA targeting MDM2 had similar effects as Nutlin-3 treatment, indicating an important role of MDM2 as a negative-feedback regulator of Figure 7 Simplified model showing the role of the MDM2/p53 axis in regulating the sensitivity to cisplatin and Nutlin-3 in wild-type p53-expressing TC cells. P53 is a transcriptional activator of p21, Fas and MDM2. Cisplatin sensitive TC cells have low levels of p21 and cisplatin-resistant TC cells, due to higher CDKN1A expression levels and lower levels of Oct4 and miR-106b family members, high levels of cytoplasmic p21, which is a key determinant of resistance to cisplatin-induced apoptosis. 19 Cisplatininduced apoptosis in TC cells also involves activation of the Fas death receptor pathway via elevated Fas membrane expression. High cytoplasmic p21 levels inhibit Fas death receptor-mediated apoptosis in cisplatin-resistant TC cells. 30 Moreover, cisplatin-induced DNA damage activates p53 and enhances release of p53 from MDM2-p53 complex, while sustained MDM2-p53 complex formation is found in cisplatin-resistant cells. Interfering in MDM2-p53 complex formation by Nutlin-3 treatment (or suppression of MDM2) substantially induces Fas expression, resulting in apoptosis of both cisplatin sensitive and resistant TC cells. Cisplatin in combination with Nutlin-3 further enhances Fas expression and sensitises cisplatin-sensitive and resistant TC cells to cisplatin-induced apoptosis. Dotted lines indicate interaction or signaling. Solid lines indicate p53-dependent transcription. Grey dotted and solid lines specify reduced activity Targeting MDM2/p53 overcomes cisplatin resistance R Koster et al p53 activity, however we cannot exclude a role for Nutlin-3-induced release of MDM2 in the observed apoptosis. These results suggest a tight regulation of MDM2 interacting with p53. Several in vitro and in vivo studies suggest an important role for p53 in the cisplatin-sensitivity of TC. 10, 11, 15, 31, 32 In contrast, other studies have failed to support a role for p53 in TC responsiveness, 13 although the involvement of the MDM2-p53 complex in the response to chemotherapy had not been thoroughly assessed. 13, 14 The present study indicates that p53 function is impeded by the interaction with MDM2 and the subsequent sequestration of p53 in the cytoplasm of cisplatin-resistant TC cells following cisplatin treatment. The strong sensitisation to cisplatin by low doses of Nutlin-3 further demonstrates the importance of MDM2 in controlling p53 following cisplatin-induced DNA damage.
Resistant and sensitive TC cells
Induction of FasL and upregulation of the Fas receptor in a p53-dependent manner has been observed in several tumour cell lines after treatment with chemotherapeutic drugs, such as cisplatin, and is related to apoptosis induction. 2, 5, [26] [27] [28] [29] [30] Previously, we have reported that the Fas/FasL system is active and functional in cisplatin-sensitive but almost inactive in cisplatin-resistant TC cell lines. 2 In the present study, we show that Nutlin-3 treatment strongly enhanced Fas membrane expression levels in TC cells. Fascinatingly, blocking of the Fas-FasL interaction in TC cells impairs apoptosis induction by Nutlin-3 as well as combined treatment with Nutlin-3 and cisplatin. However, involvement of other genes in this pathway cannot be excluded, because p53 has been shown to transcriptionally activate several other genes involved in apoptosis via the Fas/FasL system after cisplatin treatment. In the cisplatin-sensitive Tera cells, besides FAS, the Fas adaptor leucine-rich repeats and death domain containing (LRDD) and a gene implicated in positive Fas regulation, pleckstrin homology-like domain, family A, member 3 (PHLDA3) were found to be regulated by p53 upon cisplatin treatment. 15 Importantly, we have observed that the Fas/FasL system also has an important role in Nutlin-3-induced apoptosis of wild-type p53-expressing AML and Hodgkin cell lines. The wild-type p53-expressing cell line OCI-AML-3, however, did not show a significant reduction in Nutlin-3-induced apoptosis after FasL blocking. This latter result can be explained by the observation that Nutlin-3-induced apoptosis was independent of transcriptional activation of p53 in these cells. 21 Our results, thus, indicate a major role for the Fas/FasL system in the response to Nutlin-3 of wild-type p53-expressing TC, AML, and Hodgkin cell lines.
We have recently reported the important protective role of elevated p21 levels in cisplatin-resistant TC cells as compared with p21 levels in cisplatin-sensitive TC cells. 19, 30 In cisplatinresistant TC cells, p21 is cytoplasmic localised thus inhibiting cisplatin-induced cyclin-dependent kinase 2 and Fasmediated apoptosis. In addition, cisplatin-or irradiationinduced upregulation of p21 does not induce cell-cycle arrest in TC cells. 19, 30 The present results indicate that cytoplasmic localised p21 blocks Nutlin-3-induced apoptosis in cisplatinresistant TC cells that are also less sensitive to Nutlin-3 compared with cisplatin-sensitive TC cells. Xia et al. 33 has not found a protective role of p21 against Nutlin-3-induced apoptosis in non-TC cell lines, though cellular localisation of p21 was not assessed. The p53-dependent induction of p21 in these non-TC cells by Nutlin-3 resulted in a cell-cycle arrest, 33 strongly suggesting nuclear localisation of p21. In contrast, in TC cells Nutlin-3 treatment did not induce cell-cycle arrest, 24, 25 probably as a result of the predominantly cytoplasmic localisation of p53-dependent p21 expression by Nutlin-3.
Treatment with higher Nutlin-3 concentrations led to a strong induction of p53, a further increase in Fas membrane expression and higher levels of apoptosis in cisplatinsensitive and -resistant TC cells. Non-apoptotic genes, such as CDKN1A, constitutively harbour high levels of the poised RNA polymerase II (RNAPII) initiation complex at their core promoters, which are converted into elongated forms shortly after stress, but reinitiate very poorly. In contrast, proapoptotic genes, including FAS, have low levels of bound RNAPII but undergo damage-induced activation through multiple rounds of efficient reinitiation. [34] [35] [36] Additionally, the co-factors apoptosis-stimulating of p53 protein 1/2 (ASPP1/2), junction mediating and regulatory protein, p53 cofactor (JMY), herpes virus-associated ubiquitin-specific protease (HAUSP), and nuclear transcription factor Y (NF-Y) enhance p53 apoptotic activity by facilitating its binding to pro-apoptotic promoters. 7, 35, 36 For instance, NF-Y is known to be an essential positive regulator of FAS transcription, whereas it represses CDKN1A promoter activity. 35, 36 Interestingly, p53 occupancy of the p21 promoter in TC cells was similar to the levels observed in non-TC cells, whereas much less p21 expression was found in TC cells. 25 In addition, p21 mRNA and protein levels remained relatively low after either Nutlin-3 25 or cisplatin treatment in TC cells as compared with other cancer cell types. 2, 19, 25, 30 Therefore, it is tempting to speculate that the Nutlin-3-induced release of the negative feedback on p53 by MDM2 further shifts the balance towards transcribing pro-apoptotic genes, for instance involved in the Fas death receptor pathway. This effect may be further enhanced by the combination of Nutlin-3 with cisplatin.
A previous study has reported that combining Nutlin-3 with other cytotoxic agents enhances the activity of these agents in wild-type p53-expressing leukaemia cells. 21 Our results show that combining non-toxic concentrations of Nutlin-3 with cisplatin sensitises both intrinsic as well as acquired cisplatin-resistant TC cells to low concentrations of cisplatin. Of interest, MDM2 inhibitors in contrast to cisplatin might be considered non-genotoxic, as demonstrated with Nutlin-3 in mice. 23 Nutlin-3 even showed protective activity in normal kidney cells against cisplatin-induced apoptosis.
37 MDM2 inhibitors have entered phase I clinical trials in haematological malignancies and solid tumours. Based on the present results, clinical trials using MDM2 inhibitors such as Nutlin-3 in combination with cisplatin to treat cancer patients with wildtype p53, for instance refractory TC patients, may be of great importance.
In conclusion, we demonstrate that the negative feedback regulator MDM2 has an important role in the sensitivity of wild-type p53-expressing TC cells to Nutlin-3 and cisplatin. Our findings show that disrupting the MDM2-p53 interaction, also in combination with cisplatin, enhances Fas death receptor-mediated apoptosis in TC cells. Targeting the MDM2/p53 axis in combination with standard cisplatin-based treatment is a therapeutic strategy warranted to pursue in cisplatin-resistant/refractory TCs.
Materials and Methods
Cell lines and reagents. A well-defined panel of cisplatin-sensitive and resistant EC cell lines 833KE, Tera, Tera-CP, Scha, and 2102EP (all expressing wild-type p53) and NCCIT (mutant p53) were used in this study. 3, 19, 30, 38, 39 Tera, Tera-CP, 2102EP, Scha, 833KE, and NCCIT were cultured and harvested as described previously. 19 The cell lines OCI-AML-3, MOLM-13, HL-60, KM-H2, L540, and L428 were maintained as described previously. 21, 22 Cisplatin was purchased from Bristol-Myers Co. (Weesp, the Netherlands), Nutlin-3 from Cayman Chemical (Huissen, the Netherlands). To block Fas/FasL interactions, cells were incubated with anti-FasL Ab NOK-1 (Becton Dickinson, Breda, the Netherlands) and azidefree IgG control (Becton Dickinson).
Drug sensitivity assay. Drug sensitivity testing was performed with the microculture tetrazolium assay as described previously. 19 Immunofluorescence. Cells were seeded on 0.01% poly-L-lycine (Sigma, Amsterdam, The Netherlands) pre-coated coverslips. After 24 h, indicated treatment cells were fixed with methanol/acetone (1 : 1) for 30 min at RT and then blocked with 1% bovine serum albumin and 1% normal goat serum in PBS for 30 min at RT. Followed by immunostaining with the corresponding antibodies and counterstained with Alexa-Fluor goat secondary antibodies (Molecular Probes, Invitrogen, Merelbeke, Belgium). Finally, cells were stained with Hoechst 33258 (Molecular Probes, Invitrogen) for 5 min, washed with PBS, and coverslips were mounted on slides with Vectashield (Vector Laboratories, Amsterdam, the Netherlands). After staining cells were analysed using a Quantimet 600S digital analysis system (Leica Microsystems, Rijswijk, The Netherlands).
IP. IP was performed with a mixture of agarose conjugated anti-p53 (DO1 & FL-393, Santa Cruz, CA, USA) as described previously. 19 SDS-polyacrylamide gel electrophoresis and immunoblotting. After 24 h, indicated treatment cells were harvested and lysates were examined by WB as described previously. 19, 30 Antibodies used are listed in Supplementary Methods.
Apoptosis. Cells were continuously incubated with cisplatin for 24 h at various concentrations. Acridine orange fluorescent staining of nuclei in unfixed cells was used to distinguish apoptotic from vital cells. 19, 30, 40 RNA interference. The siRNA specific for human p53, MDM2, FasL, and negative control (scrambled) were purchased from Eurogentec (Maastricht, the Netherlands). TC cells were transfected in six-well plates with 5 ml of 20 mM siRNA duplex or siRNA anti-sense using Oligofectamine reagent according to the manufacturer's instructions (Invitrogen, Merelbeke, Belgium). After 24 h, cells were treated with cisplatin. 24 h after the treatment cells were harvested for protein isolation. Alternatively, in order to perform an apoptosis assay, at 24 h after transfection, cells were harvested and plated in 96-well plate. The day after, cells were treated with cisplatin. All sequences are listed in Supplementary Methods. Statistical analysis. Results of at least three experiments are expressed as mean±(standard deviation) S.D. Student's unpaired t-test was used to compare values of test and control samples. All tests were two-sided and differences were considered to indicate significance when Po0.05.
